Hyperlipidemia is one of the most risk factors involved in the development of cardiovascular disease. As a consequence of hyperlipidemia treatment, a high demand for new oral antihyperlipidemic drugs is required. The present study was designed to investigate the potential effect of a novel compound N-[4-benzoylphenyl]-1H-indole- 2-carboxamide on diet-induced hyperlipidemic (prepared by mixing cholesterol 0.5%, 0.25 % cholic acid, 20% fat and 2% corn oil with standard powdered animal food for two months) , triton-induced hyperlipidemic (by intraperitoneal injection of Triton WR-1339 250 mg/kg body weight) and alloxan-induced hyperglycemic rats (150 mg/kg body weight injected intraperitoneally). Lipid profiles [Total cholesterol (TC), Triglyceride (TG), Low Density Lipoprotein (LDL) and High Density Lipoprotein (HDL)] in all groups showed significant (p < 0.05) changes (±) before treatment. After 24 hrs of treatment with N-[4-benzoylphenyl]-1H-indole-2-carboxamide (15 mg/kg body weight), significant decrease (p <0.05) in serum cholesterol level 60%, , triglyceride 33-45%, LDL 32% and increase HDL 58% levels. Nevertheless, antihyperlipidemic fenofibrate - used as standard reference - showed parallel results to the novel compound. In addition, body weight of diet-induced hyperlipidemic rats decreased about 20%. On the other hand, the novel compound showed no significant effect on glucose level of hyperglycemic rats. In conclusion, the results indicate that N-[4-benzoylphenyl]-1H-indole-2-carboxamide possesses significant antihyperlipidemic activity and may conserve a promising potential effect in the treatment of hyperlipidemia correlated to heart diseases.